Mazdutide 6mg

Mazdutide (IBI362, OXM3) is a GLP-1/Glucagon dual agonist being developed by Innovent Biologics primarily for the Chinese and Asian patient populations, where it has undergone extensive Phase 2 and Phase 3 clinical investigation for both obesity and type 2 diabetes management. Its dual receptor mechanism mirrors survodutide's pharmacological approach — GLP-1 receptor agonism for appetite suppression and insulin secretion paired with glucagon receptor agonism for hepatic fat mobilization and thermogenesis — but with a distinct molecular structure and development profile optimized through Innovent's SAIL (Structured Amide Insertion Ligation) technology.

The pharmacological rationale for GLP-1/Glucagon dual agonism in mazdutide is the same mechanistic advantage shared across this class: glucagon receptor agonism contributes benefits that GLP-1 alone cannot provide. Glucagon drives hepatic lipolysis — increasing fatty acid oxidation and reducing hepatic triglyceride content — which is directly relevant to the high prevalence of non-alcoholic fatty liver disease (NAFLD) in the metabolic syndrome population that most benefits from GLP-1-based therapy. Glucagon also activates brown adipose tissue (BAT) thermogenesis through β-3 adrenergic and sympathetic nervous system cross-talk, increasing energy expenditure beyond the appetite suppression mediated by GLP-1. Together, these mechanisms produce a more favorable metabolic shift than GLP-1 monotherapy.

Phase 2 clinical data for mazdutide in Chinese patients with obesity demonstrated weight reductions of 10–14% over 24 weeks at optimal doses — highly significant for a Phase 2 duration and consistent with the GLP-1/glucagon dual agonist class. Importantly, mazdutide showed significant HbA1c reduction alongside weight loss, confirming the GLP-1 component's glycemic efficacy. Phase 3 trials (GLORY program) are ongoing for both obesity and T2D indications in China, with potential for broader global regulatory applications pending those outcomes.

The distinction from semaglutide lies in the glucagon component and its hepatic metabolic effects. Head-to-head comparisons in animal models and Phase 2 human data suggest GLP-1/glucagon dual agonists produce greater reduction in liver fat than GLP-1 monotherapy — a clinically meaningful differentiator given the extremely high NAFLD/NASH prevalence in the obese metabolic syndrome population. This hepatic dimension may ultimately drive mazdutide's adoption as a preferred agent in populations where metabolic liver disease is a co-primary therapeutic target alongside weight management.

The SAIL technology used in mazdutide's engineering improves protease stability and extends half-life through structured molecular modifications — addressing one of the key pharmaceutical challenges in peptide drug development (enzymatic degradation). This technical improvement contributes to the once-weekly dosing profile that makes mazdutide practical for long-term obesity management.

Research compound reflecting late-stage clinical development. Weekly subcutaneous injection, dose escalation from 1.2mg to 6mg target dose per clinical trial protocols.